Hsbc Holdings PLC Deciphera Pharmaceuticals, Inc. Transaction History

Hsbc Holdings PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$13.58 - $17.36 $46,362 - $59,267	-3,414 Reduced 11.51%	26,256 $413,000
Q4 2023 Feb 12, 2024	BUY	$10.11 - $16.54 $111,786 - $182,882	11,057 Added 59.4%	29,670 $478,000
Q3 2023 Nov 13, 2023	SELL	$12.46 - $15.48 $1.48 Million - $1.84 Million	-118,997 Reduced 86.47%	18,613 $236,000
Q2 2023 Aug 11, 2023	BUY	$13.28 - $15.96 $1.83 Million - $2.2 Million	137,610 New	137,610 $1.94 Million
Q2 2022 Aug 11, 2022	SELL	$9.11 - $13.98 $106,860 - $163,985	-11,730 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.87 - $11.11 $3,270 - $5,288	476 Added 4.23%	11,730 $110,000
Q4 2021 Feb 11, 2022	BUY	$7.7 - $37.13 $86,655 - $417,861	11,254 New	11,254 $109,000
Q1 2021 May 14, 2021	SELL	$40.39 - $56.73 $293,150 - $411,746	-7,258 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$51.77 - $66.18 $375,746 - $480,334	7,258 New	7,258 $414,000
Q4 2019 Feb 14, 2020	SELL	$31.7 - $69.93 $308,092 - $679,649	-9,719 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$19.95 - $38.85 $193,894 - $377,583	9,719 New	9,719 $330,000

293K

500

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.